Insulet Co. (NASDAQ:PODD) Shares Bought by Jennison Associates LLC

Jennison Associates LLC grew its stake in Insulet Co. (NASDAQ:PODD) by 21.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 158,342 shares of the medical instruments supplier’s stock after purchasing an additional 28,375 shares during the period. Jennison Associates LLC’s holdings in Insulet were worth $41,338,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Baillie Gifford & Co. increased its stake in Insulet by 20.7% in the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock valued at $529,669,000 after buying an additional 389,639 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Insulet by 1.3% in the third quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier’s stock valued at $403,339,000 after acquiring an additional 22,850 shares in the last quarter. Westfield Capital Management Co. LP increased its stake in shares of Insulet by 27.6% during the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after acquiring an additional 163,388 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Insulet by 43.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock worth $148,091,000 after purchasing an additional 193,839 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its position in Insulet by 0.9% in the third quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock valued at $81,719,000 after purchasing an additional 3,113 shares during the period.

Insider Activity at Insulet

In related news, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the sale, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. This represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on PODD. Wells Fargo & Company boosted their target price on Insulet from $290.00 to $305.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. BTIG Research increased their price objective on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Barclays raised their target price on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Canaccord Genuity Group upped their price target on shares of Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Finally, Raymond James raised their price objective on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $272.81.

Insulet Price Performance

Insulet stock opened at $278.48 on Wednesday. The stock has a market capitalization of $19.53 billion, a P/E ratio of 47.68, a P/E/G ratio of 3.49 and a beta of 1.23. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $286.39. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The firm’s 50-day moving average is $269.18 and its two-hundred day moving average is $239.68.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 EPS for the quarter, topping the consensus estimate of $0.77 by $0.13. Insulet had a net margin of 21.22% and a return on equity of 27.98%. The firm had revenue of $543.90 million during the quarter, compared to analysts’ expectations of $518.50 million. During the same period in the previous year, the company earned $0.71 EPS. Equities analysts predict that Insulet Co. will post 3.22 earnings per share for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.